Compare SG & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SG | BWAY |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 641.7M | 578.5M |
| IPO Year | 2021 | 2011 |
| Metric | SG | BWAY |
|---|---|---|
| Price | $5.85 | $14.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 2 |
| Target Price | $8.43 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 6.5M | 166.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $679,474,000.00 | N/A |
| Revenue This Year | $7.60 | $309.69 |
| Revenue Next Year | $8.45 | $26.21 |
| P/E Ratio | ★ $7.17 | $81.98 |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $4.49 | $11.77 |
| 52 Week High | $10.63 | $26.63 |
| Indicator | SG | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 44.01 |
| Support Level | $5.07 | $14.13 |
| Resistance Level | $6.12 | $14.85 |
| Average True Range (ATR) | 0.42 | 0.88 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 43.09 | 6.94 |
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.